New Delhi: Veteran Bengali Soumitra Chatterjee who has been battling COVID-19 since October 6, continues to be in a critical condition. According to the latest report, the 85-year old actor’s condition has deteriorated and he has stopped responding to treatments.

"Heartbroken To Find Fake Pics Of My Covid-Afflicted Father": Soumitra Chatterjee's Daughter Pulls Up Rumour-Mongers

An official told PTI, “The health condition of legendary Bengali actor Soumitra Chatterjee on Saturday deteriorated as he has stopped responding to treatments, adding to the worries of the doctors treating him at a private hospital here.”

Dr. Arindam Kar who is leading the team of doctors treating the actor told PTI, “Though the 85-year-old's organs were functioning ‘well’, the platelet count has dropped and the level of urea and sodium in his blood has gone up. "(Soumitra) Chatterjee's consciousness is little down compared to what it was 72 hours ago. Not very sure which way it is heading to. We have received reports of tests and we can deduce that the COVID encephalopathy is progressing.”

The doctor further added that the ‘Apur Sansar’ actor is not responding to treatments despite the use of steroids and other prolonged efforts.

Dr. Kar added, “Though his lungs and blood pressure are still working well, there are points to be worried of. His platelet count has come down. We are trying to find out the reason for that. We will take some tough calls tomorrow.”

“We are trying our best. But sometime the best efforts are not enough for someone who is suffering from these disease at his age”, concluded the doctor.

Soumitra Chatterjee is best known for his collaboration with the Oscar award-winning director Satyajit Ray with whom he has worked in 14 films. His debut film ‘Apur Sansar’ was written and directed by the master himself. This film also marked Sharmila Tagore’s debut work in the film industry.

Hrithik Roshan Has Nearly Spent A Whopping Rs 100 Crore For His New Lavish ‘Mansion-In-The-Air’: Report

Watch this space for more updates.